Reduction of COVID 19 Transmission to Health Care Professionals

NCT04462627 | Completed

• 1 other identifier: CHUB-BDS-COVID19
• Study Type: interventional
• Target: 566
• Locations: 1 country
• Sites: 1

Brief Summary

When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate. The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs. It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups. In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.

Conditions

COVID 19

Outcome Measures

Primary Outcomes (11)

• Anti-A antibody concentration

  Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  baseline

• Anti-A antibody concentration

  Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Day 4

• Anti-A antibody concentration

  Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Week 1

• Anti-A antibody concentration

  Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Week 2

• Anti-A antibody concentration

  Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Week 3

• Anti-B antibody concentration

  Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  baseline

• Anti-B antibody concentration

  Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Day 4

• Anti-B antibody concentration

  Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Week 1

• Anti-B antibody concentration

  Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Week 2

• Anti-B antibody concentration

  Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.

  Week 3

• Blood group

  Blood group (ABO/LE)

  baseline

Study Arms (3)

Covid 19 positive patients

EXPERIMENTAL

Diagnostic Test: Blood group determination; Diagnostic Test: Antibody titration

Covid 19 negative patients

EXPERIMENTAL

Diagnostic Test: Blood group determination; Diagnostic Test: Antibody titration

Untested healthy volunteers

EXPERIMENTAL

Diagnostic Test: Blood group determination; Diagnostic Test: Antibody titration; Dietary Supplement: Probiotic

Interventions

Blood group determination DIAGNOSTIC_TEST

Determination of the blood group (ABO/LE)

Covid 19 negative patients; Covid 19 positive patients; Untested healthy volunteers

Antibody titration DIAGNOSTIC_TEST

Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.

Covid 19 negative patients; Covid 19 positive patients; Untested healthy volunteers

Probiotic DIETARY_SUPPLEMENT

Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).

Untested healthy volunteers

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• COVID19 positive patients admitted within the CHU Brugmann Hospital

You may not qualify if:

• None

Sponsors & Collaborators

• Hanane EL KENZ: lead

Study Sites (1)

CHU Brugmann

Brussels, 1020, Belgium

Location

MeSH Terms

Conditions

COVID-19

Interventions

Probiotics

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Dietary Supplements; Food; Diet, Food, and Nutrition; Physiological Phenomena; Food and Beverages

Study Officials

• Hanane El Kenz, MD

  CHU Brugmann

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head Physician of the Blood Bank

Study Record Dates

• First Submitted: July 7, 2020
• First Posted: July 8, 2020
• Study Start: April 14, 2020
• Primary Completion: April 11, 2022
• Study Completion: April 11, 2022
• Last Updated: July 20, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)